Biblio Discovery — Demo Discovery Service

27 results for "Rangi Kandane-Rathnayake"

Showing 1–20 · 0.31 seconds · RSS

  1. Journal Article

    Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study

    Worawit Louthrenoo; Nuntana Kasitanon; Eric Morand et al.

    Arthritis Research & Therapy, Vol. 22 No. 1 · 2020 · English · DOAJ Scopus

    Abstract Background The utility of generic health-related quality of life (HRQoL) questionnaires in patients with systemic lupus erythematosus (SLE) is uncertain. We compared the performance of generic (SF36) and specific (SLEQOL) HRQoL surveys by examining their associations with the Global Rating…

  2. Journal Article

    Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data

    Rangi Kandane-Rathnayake; Eric F Morand; Kathryn Connelly et al.

    Lupus Science and Medicine, Vol. 13 No. 1 · 2026 · English · DOAJ Scopus

    Objective Outcome measures used in SLE randomised controlled trials (RCTs) have impeded trial success and drug approval. In an ongoing global project to develop a novel outcome measure for SLE RCTs, a ‘core set’ of domains with which to determine treatment response was chosen via consensus. We…

  3. Journal Article

    Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis

    Rangi Kandane-Rathnayake; Sarah Jones; Eric Morand et al.

    Lupus Science and Medicine, Vol. 9 No. 1 · 2022 · English · DOAJ Scopus

    Objectives Type 1 interferon (IFN) is key to the pathogenesis of SLE, evidenced by the expression of IFN-stimulated genes (ISGs) in most patients, but the clinical utility of serial ISG assessment remains unknown. With the emergence of IFN-blocking drugs, we aimed to examine IFN status in relation…

  4. Journal Article

    Clinical associations of cognitive dysfunction in systemic lupus erythematosus

    Rangi Kandane-Rathnayake; Eric F Morand; Vera Golder et al.

    Lupus Science and Medicine, Vol. 10 No. 1 · 2023 · English · DOAJ Scopus

    Objective Cognitive dysfunction in SLE is common, but clinical risk factors are poorly understood. This study aims to explore the associations of cognitive dysfunction in SLE with disease activity, organ damage, biomarkers and medications.Methods We performed cross-sectional cognitive assessment…

  5. Journal Article

    Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus

    Fabien B Vincent; Alberta Y Hoi; Fabienne Mackay et al.

    Lupus Science and Medicine, Vol. 7 No. 1 · 2020 · English · DOAJ Scopus

    Objective Fas/Fas ligand (FasL) and B cell-activating factor (BAFF) signalling have pivotal roles in SLE pathogenesis. We investigated the clinical associations of serum concentrations of soluble Fas (sFas) and soluble FasL (sFasL) in SLE and their relationship with BAFF.Methods Serum sFas and…

  6. Journal Article

    Serum IgA autoantibody profiling in systemic lupus erythematosus reveals associations with disease phenotypes

    Fabien B Vincent; Alberta Y Hoi; Rangi Kandane-Rathnayake et al.

    RMD Open, Vol. 12 No. 3 · 2026 · English · DOAJ Scopus

    Background Knowledge of the role of IgA isotype autoantibodies in systemic lupus erythematosus (SLE) is lacking. We aimed to explore associations between serum IgA autoantibody profiles and SLE clinical phenotypes using an unbiased approach.Methods 1613 serum IgA autoantibodies were quantified in…

  7. Journal Article

    Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus

    Rachel Mende; Fabien B. Vincent; Rangi Kandane-Rathnayake et al.

    Frontiers in Immunology, Vol. 9 · 2018 · English · DOAJ Scopus

    Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease characterized by biological and clinical heterogeneity. The interleukin (IL)-1 superfamily is a group of innate cytokines that contribute to pathogenesis in many autoimmune diseases. IL-1β and IL-18 are two members that…

  8. Journal Article

    Serum autoantibody profiling in systemic lupus erythematosus reveals associations with low disease activity and remission

    Laura E. Eades; William A. Figgett; Katie Lennard et al.

    Frontiers in Lupus, Vol. 4 · 2026 · English · DOAJ

    BackgroundKnowledge of autoantibody specificities and their clinical associations in systemic lupus erythematosus (SLE) is largely limited to panels testing a finite number of autoantibodies. We aimed to explore high-plex serum autoantibody profiles in SLE and examine associations with…

  9. Journal Article

    Targeting DORIS Remission and LLDAS in SLE: A Review

    Agner R. Parra Sánchez; Ronald F. van Vollenhoven; Eric F. Morand et al.

    Rheumatology and Therapy, Vol. 10 No. 6 · 2023 · English · DOAJ Scopus

    Abstract Remission is the established therapeutic goal for patients with systemic lupus erythematosus (SLE) and is currently defined by the widely adopted Definition Of Remission In SLE (DORIS) criteria. Attainment of remission is rare in the clinical setting, thus an alternative, pragmatic…

  10. Journal Article

    High disease activity persists in adults with childhood-onset lupus

    Rangi Kandane-Rathnayake; Eric F Morand; Mandana Nikpour et al.

    Lupus Science and Medicine, Vol. 13 No. 2 · 2026 · English · DOAJ Scopus

    Objective Childhood-onset SLE (cSLE) is often described as more severe than adult-onset disease (aSLE) based largely on cross-sectional studies. We examined differences in disease characteristics, medication use and long-term outcomes between cSLE and patients with aSLE in adulthood using…

  11. Journal Article

    Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study

    Rangi Kandane-Rathnayake; Rachel Koelmeyer; Shereen Oon et al.

    Arthritis Research & Therapy, Vol. 28 No. 1 · 2026 · English · DOAJ Scopus

    Abstract Background Anti-ribonucleoprotein (RNP) (auto)antibodies are frequently detected in patients with systemic lupus erythematosus (SLE) although their associations with SLE disease activity remain incompletely understood. We compared patient characteristics, including disease severity…

  12. Journal Article

    Smith-specific regulatory T cells halt the progression of lupus nephritis

    Peter J. Eggenhuizen; Rachel M. Y. Cheong; Cecilia Lo et al.

    Nature Communications, Vol. 15 No. 1 · 2024 · English · DOAJ Scopus

    Abstract Antigen-specific regulatory T cells (Tregs) suppress pathogenic autoreactivity and are potential therapeutic candidates for autoimmune diseases such as systemic lupus erythematosus (SLE). Lupus nephritis is associated with autoreactivity to the Smith (Sm) autoantigen and the human…

  13. Journal Article

    Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study

    Ricardo Azêdo de Luca Montes; Molla Huq; Timothy Godfrey et al.

    Advances in Rheumatology, Vol. 64 No. 1 · 2024 · English · DOAJ Scopus

    Abstract Background This study examines the association of standard-of-care systemic lupus erythematosus (SLE) medications with key outcomes such as low disease activity attainment, flares, damage accrual, and steroid-sparing, for which there is current paucity of data. Methods The Asia Pacific…

  14. Journal Article

    Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus

    Rangi Kandane-Rathnayake; Sang-Cheol Bae; Zhanguo Li et al.

    Lupus Science and Medicine, Vol. 12 No. 1 · 2025 · English · DOAJ Scopus

    Objective To estimate the prevalence of organ damage (damage) and flare and to examine longitudinal associations between flares and subsequent damage accrual, in patients with systemic lupus erythematosus (SLE).Methods Patients enrolled in the Asia Pacific Lupus Collaboration cohort with ≥3 years…

  15. Journal Article

    Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus

    Tsutomu Takeuchi; Yoshiya Tanaka; Rangi Kandane-Rathnayake et al.

    Lupus Science and Medicine, Vol. 11 No. 2 · 2024 · English · DOAJ Scopus

    Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological…

  16. Journal Article

    Informing trial measurement in systemic lupus erythematosus: frequency of domain-specific disease activity in a multinational cohort

    Tsutomu Takeuchi; Yoshiya Tanaka; Rangi Kandane-Rathnayake et al.

    Lupus Science and Medicine, Vol. 12 No. 2 · 2025 · English · DOAJ Scopus

    Objective To report the prevalence of disease activity in individual SLE organ domains, including prevalence stratified by the most common disease activity cut-off score for clinical trial eligibility (SLE Disease Activity Index 2000; SLEDAI-2K ≥6).Methods We used data from a multinational…

  17. Journal Article

    Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort

    Rangi Kandane-Rathnayake; Worawit Louthrenoo; CS Lau et al.

    Arthritis Research & Therapy, Vol. 27 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Background Emerging therapies have the potential to be used in patients with severe refractory systemic lupus erythematosus (srSLE), but no agreed definition of srSLE exists. We evaluated a pilot srSLE definition to assess whether a set of disease activity and treatment thresholds could…

  18. Journal Article

    ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study

    Rangi Kandane-Rathnayake; Worawit Louthrenoo; Alberta Hoi et al.

    Arthritis Research & Therapy, Vol. 24 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Background The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to…